{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T14:23:16Z","timestamp":1740147796399,"version":"3.37.3"},"reference-count":112,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2022,5,26]],"date-time":"2022-05-26T00:00:00Z","timestamp":1653523200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,5,26]],"date-time":"2022-05-26T00:00:00Z","timestamp":1653523200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["P30 026877"],"award-info":[{"award-number":["P30 026877"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Neurol Neurosci Rep"],"published-print":{"date-parts":[[2022,6]]},"DOI":"10.1007\/s11910-022-01194-7","type":"journal-article","created":{"date-parts":[[2022,5,26]],"date-time":"2022-05-26T02:02:16Z","timestamp":1653530536000},"page":"313-325","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Advances in the Treatment of Thyroid Eye Disease Associated Extraocular Muscle Myopathy and Optic Neuropathy"],"prefix":"10.1007","volume":"22","author":[{"given":"Tracy J.","family":"Lu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Linus","family":"Amarikwa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Connie M.","family":"Sears","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3110-1210","authenticated-orcid":false,"given":"Andrea L.","family":"Kossler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,5,26]]},"reference":[{"issue":"8","key":"1194_CR1","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1056\/NEJMra0905750","volume":"362","author":"RS Bahn","year":"2010","unstructured":"Bahn RS. Graves\u2019 ophthalmopathy. N Engl J Med. 2010;362(8):726\u201338. https:\/\/doi.org\/10.1056\/NEJMra0905750.","journal-title":"N Engl J Med"},{"issue":"3\u20134","key":"1194_CR2","first-page":"177","volume":"5","author":"FF Rundle","year":"1945","unstructured":"Rundle FF, Wilson CW. Development and course of exophthalmos and ophthalmoplegia in Graves\u2019 disease with special reference to the effect of thyroidectomy. Clin Sci. 1945;5(3\u20134):177\u201394.","journal-title":"Clin Sci"},{"issue":"2","key":"1194_CR3","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1111\/j.1365-2265.2005.02186.x","volume":"62","author":"CB Terwee","year":"2005","unstructured":"Terwee CB, Prummel MF, Gerding MN, Kahaly GJ, Dekker FW, Wiersinga WM. Measuring disease activity to predict therapeutic outcome in Graves\u2019 ophthalmopathy. Clin Endocrinol (Oxf). 2005;62(2):145\u201355. https:\/\/doi.org\/10.1111\/j.1365-2265.2005.02186.x.","journal-title":"Clin Endocrinol (Oxf)"},{"key":"1194_CR4","doi-asserted-by":"publisher","first-page":"543","DOI":"10.2147\/opth.s5228","volume":"3","author":"ED Bothun","year":"2009","unstructured":"Bothun ED, Scheurer RA, Harrison AR, Lee MS. Update on thyroid eye disease and management. Clin Ophthalmol. 2009;3:543\u201351. https:\/\/doi.org\/10.2147\/opth.s5228.","journal-title":"Clin Ophthalmol"},{"issue":"4","key":"1194_CR5","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1046\/j.1365-2265.1996.8220832.x","volume":"45","author":"J Pfeilschifter","year":"1996","unstructured":"Pfeilschifter J, Ziegler R. Smoking and endocrine ophthalmopathy: impact of smoking severity and current vs lifetime cigarette consumption. Clin Endocrinol (Oxf). 1996;45(4):477\u201381. https:\/\/doi.org\/10.1046\/j.1365-2265.1996.8220832.x.","journal-title":"Clin Endocrinol (Oxf)"},{"key":"1194_CR6","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/s40662-014-0009-8","volume":"1","author":"C McAlinden","year":"2014","unstructured":"McAlinden C. An overview of thyroid eye disease. Eye Vis (Lond). 2014;1:9. https:\/\/doi.org\/10.1186\/s40662-014-0009-8.","journal-title":"Eye Vis (Lond)"},{"issue":"1","key":"1194_CR7","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1097\/iop.0000000000001437","volume":"36","author":"CJ Heisel","year":"2020","unstructured":"Heisel CJ, Riddering AL, Andrews CA, Kahana A. Serum vitamin D deficiency is an independent risk factor for thyroid eye disease. Ophthalmic Plast Reconstr Surg. 2020;36(1):17\u201320. https:\/\/doi.org\/10.1097\/iop.0000000000001437.","journal-title":"Ophthalmic Plast Reconstr Surg"},{"issue":"3","key":"1194_CR8","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1097\/IOP.0000000000001211","volume":"35","author":"LA Habib","year":"2019","unstructured":"Habib LA, Godfrey KJ, Mathews P, De Rojas J, Kazim M. Association of risk of obstructive sleep apnea with thyroid eye disease: compressive optic neuropathy. Ophthalmic Plast Reconstr Surg. 2019;35(3):232\u20134. https:\/\/doi.org\/10.1097\/IOP.0000000000001211.","journal-title":"Ophthalmic Plast Reconstr Surg"},{"issue":"3S","key":"1194_CR9","doi-asserted-by":"publisher","first-page":"S58","DOI":"10.1097\/IOP.0000000000001809","volume":"37","author":"KJ Godfrey","year":"2021","unstructured":"\u2022 Godfrey KJ, Schmuter G, Hu B, et al. Prospective correlation of risk of obstructive sleep apnea with severe clinical features of thyroid eye disease. Ophthalmic Plast Reconstr Surg. 2021;37(3S):S58\u201361. https:\/\/doi.org\/10.1097\/IOP.0000000000001809. This paper reports a significant correlation between obstructive sleep apnea and progression to dysthyroid optic neuropathy.","journal-title":"Ophthalmic Plast Reconstr Surg"},{"issue":"4","key":"1194_CR10","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1097\/iop.0000000000001871","volume":"37","author":"S Rath","year":"2021","unstructured":"Rath S, Pattnaik M, Tripathy D, Mohapatra S, Panigrahy B, Ali MH. Sight-threatening thyroid eye disease: role of diabetes mellitus and interaction with other risk factors. Ophthalmic Plast Reconstr Surg. 2021;37(4):352\u201360. https:\/\/doi.org\/10.1097\/iop.0000000000001871.","journal-title":"Ophthalmic Plast Reconstr Surg"},{"issue":"1","key":"1194_CR11","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1111\/cxo.12472","volume":"100","author":"DL Weiler","year":"2017","unstructured":"Weiler DL. Thyroid eye disease: a review. Clin Exp Optom. 2017;100(1):20\u20135. https:\/\/doi.org\/10.1111\/cxo.12472.","journal-title":"Clin Exp Optom"},{"issue":"3","key":"1194_CR12","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1016\/j.beem.2011.11.007","volume":"26","author":"PJ Dolman","year":"2012","unstructured":"Dolman PJ. Evaluating Graves\u2019 orbitopathy. Best Pract Res Clin Endocrinol Metab. 2012;26(3):229\u201348. https:\/\/doi.org\/10.1016\/j.beem.2011.11.007.","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"issue":"1","key":"1194_CR13","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1046\/j.1365-2265.1997.2331047.x","volume":"47","author":"MP Mourits","year":"1997","unstructured":"Mourits MP, Prummel MF, Wiersinga WM, Koornneef L. Clinical activity score as a guide in the management of patients with Graves\u2019 ophthalmopathy. Clin Endocrinol (Oxf). 1997;47(1):9\u201314. https:\/\/doi.org\/10.1046\/j.1365-2265.1997.2331047.x.","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"3","key":"1194_CR14","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1530\/EJE-07-0666","volume":"158","author":"L Bartalena","year":"2008","unstructured":"Bartalena L, Baldeschi L, Dickinson A, et al. Consensus statement of the European Group on Graves\u2019 orbitopathy (EUGOGO) on management of GO. Eur J Endocrinol. 2008;158(3):273\u201385.","journal-title":"Eur J Endocrinol"},{"issue":"2","key":"1194_CR15","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1016\/s0002-9394(14)70585-9","volume":"121","author":"GB Bartley","year":"1996","unstructured":"Bartley GB, Fatourechi V, Kadrmas EF, et al. The treatment of Graves\u2019 ophthalmopathy in an incidence cohort. Am J Ophthalmol. 1996;121(2):200\u20136. https:\/\/doi.org\/10.1016\/s0002-9394(14)70585-9.","journal-title":"Am J Ophthalmol"},{"issue":"4","key":"1194_CR16","doi-asserted-by":"publisher","first-page":"1443","DOI":"10.1210\/jc.2012-3873","volume":"98","author":"ML Tanda","year":"2013","unstructured":"Tanda ML, Piantanida E, Liparulo L, et al. Prevalence and natural history of Graves\u2019 orbitopathy in a large series of patients with newly diagnosed Graves\u2019 hyperthyroidism seen at a single center. J Clin Endocrinol Metab. 2013;98(4):1443\u20139. https:\/\/doi.org\/10.1210\/jc.2012-3873.","journal-title":"J Clin Endocrinol Metab"},{"issue":"8","key":"1194_CR17","doi-asserted-by":"publisher","first-page":"1707","DOI":"10.1007\/s40618-020-01479-z","volume":"44","author":"S Ippolito","year":"2021","unstructured":"Ippolito S, Cusini C, Lasalvia P, et al. Change in newly diagnosed Graves\u2019 disease phenotype between the twentieth and the twenty-first centuries: meta-analysis and meta-regression. J Endocrinol Invest. 2021;44(8):1707\u201318. https:\/\/doi.org\/10.1007\/s40618-020-01479-z.","journal-title":"J Endocrinol Invest"},{"issue":"6","key":"1194_CR18","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1097\/00004728-197903060-00019","volume":"3","author":"DR Enzmann","year":"1979","unstructured":"Enzmann DR, Donaldson SS, Kriss JP. Appearance of Graves-disease on orbital computed-tomography. J Comput Assist Tomogr. 1979;3(6):815\u20139.","journal-title":"J Comput Assist Tomogr"},{"issue":"3","key":"1194_CR19","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1148\/radiology.177.3.2243967","volume":"177","author":"RA Nugent","year":"1990","unstructured":"Nugent RA, Belkin RI, Neigel JM, et al. Graves orbitopathy: correlation of CT and clinical findings. Radiology. 1990;177(3):675\u201382. https:\/\/doi.org\/10.1148\/radiology.177.3.2243967.","journal-title":"Radiology"},{"key":"1194_CR20","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcjo.2021.04.025","author":"RE Tanenbaum","year":"2021","unstructured":"Tanenbaum RE, Lobo R, Kahana A, Wester ST. Advances in magnetic resonance imaging of orbital disease. Can J Ophthalmol. 2021. https:\/\/doi.org\/10.1016\/j.jcjo.2021.04.025.","journal-title":"Can J Ophthalmol"},{"issue":"4S Suppl 1","key":"1194_CR21","doi-asserted-by":"publisher","first-page":"S41","DOI":"10.1097\/IOP.0000000000001139","volume":"34","author":"LC Siakallis","year":"2018","unstructured":"Siakallis LC, Uddin JM, Miszkiel KA. Imaging investigation of thyroid eye disease. Ophthalmic Plast Reconstr Surg. 2018;34(4S Suppl 1):S41\u201351. https:\/\/doi.org\/10.1097\/IOP.0000000000001139.","journal-title":"Ophthalmic Plast Reconstr Surg"},{"key":"1194_CR22","doi-asserted-by":"publisher","DOI":"10.1097\/IOP.0000000000002072","author":"C Tran","year":"2021","unstructured":"Tran C, Pham CM, Simmons BA, Warner LL, Fuhrmeister LJ, Shriver EM. Echographic assessment of extraocular muscle response to teprotumumab. Ophthalmic Plast Reconstr Surg. 2021. https:\/\/doi.org\/10.1097\/IOP.0000000000002072.","journal-title":"Ophthalmic Plast Reconstr Surg"},{"issue":"3","key":"1194_CR23","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1016\/s0002-9394(14)72960-5","volume":"118","author":"JL Demer","year":"1994","unstructured":"Demer JL, Kerman BM. Comparison of standardized echography with magnetic resonance imaging to measure extraocular muscle size. Am J Ophthalmol. 1994;118(3):351\u201361. https:\/\/doi.org\/10.1016\/s0002-9394(14)72960-5.","journal-title":"Am J Ophthalmol"},{"issue":"2","key":"1194_CR24","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1111\/j.1600-0420.2006.00807.x","volume":"85","author":"G Lennerstrand","year":"2007","unstructured":"Lennerstrand G, Tian S, Isberg B, et al. Magnetic resonance imaging and ultrasound measurements of extraocular muscles in thyroid-associated ophthalmopathy at different stages of the disease. Acta Ophthalmol Scand. 2007;85(2):192\u2013201. https:\/\/doi.org\/10.1111\/j.1600-0420.2006.00807.x.","journal-title":"Acta Ophthalmol Scand"},{"issue":"12","key":"1194_CR25","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1038\/nrendo.2013.193","volume":"9","author":"L Bartalena","year":"2013","unstructured":"Bartalena L. Diagnosis and management of Graves disease: a global overview. Nat Rev Endocrinol. 2013;9(12):724\u201334. https:\/\/doi.org\/10.1038\/nrendo.2013.193.","journal-title":"Nat Rev Endocrinol"},{"issue":"1","key":"1194_CR26","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1097\/01.iop.0000192649.23508.f7","volume":"22","author":"LR Dragan","year":"2006","unstructured":"Dragan LR, Seiff SR, Lee DC. Longitudinal correlation of thyroid-stimulating immunoglobulin with clinical activity of disease in thyroid-associated orbitopathy. Ophthalmic Plast Reconstr Surg. 2006;22(1):13\u20139. https:\/\/doi.org\/10.1097\/01.iop.0000192649.23508.f7.","journal-title":"Ophthalmic Plast Reconstr Surg"},{"issue":"5","key":"1194_CR27","doi-asserted-by":"publisher","first-page":"2123","DOI":"10.1210\/jc.2009-2470","volume":"95","author":"S Lytton","year":"2010","unstructured":"Lytton S, Ponto K, Kanitz M, Matheis N, Kohn L, Kahaly G. A novel thyroid stimulating immunoglobulin bioassay is a functional indicator of activity and severity of Graves\u2019 orbitopathy. J Clin Endocrinol Metab. 2010;95(5):2123\u201331.","journal-title":"J Clin Endocrinol Metab"},{"key":"1194_CR28","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.jaut.2015.07.009","volume":"64","author":"HJ Lee","year":"2015","unstructured":"Lee HJ, Li CW, Hammerstad SS, Stefan M, Tomer Y. Immunogenetics of autoimmune thyroid diseases: a comprehensive review. J Autoimmun. 2015;64:82\u201390. https:\/\/doi.org\/10.1016\/j.jaut.2015.07.009.","journal-title":"J Autoimmun"},{"issue":"1","key":"1194_CR29","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1136\/bjophthalmol-2015-307399","volume":"100","author":"JJ Khong","year":"2016","unstructured":"Khong JJ, McNab AA, Ebeling PR, Craig JE, Selva D. Pathogenesis of thyroid eye disease: review and update on molecular mechanisms. Br J Ophthalmol. 2016;100(1):142\u201350. https:\/\/doi.org\/10.1136\/bjophthalmol-2015-307399.","journal-title":"Br J Ophthalmol"},{"issue":"2","key":"1194_CR30","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1097\/WNO.0000000000000132","volume":"34","author":"SJ Shan","year":"2014","unstructured":"Shan SJ, Douglas RS. The pathophysiology of thyroid eye disease. J Neuroophthalmol. 2014;34(2):177\u201385. https:\/\/doi.org\/10.1097\/WNO.0000000000000132.","journal-title":"J Neuroophthalmol"},{"issue":"16","key":"1194_CR31","doi-asserted-by":"publisher","first-page":"1552","DOI":"10.1056\/NEJMra1510030","volume":"375","author":"TJ Smith","year":"2016","unstructured":"Smith TJ, Hegedus L. Graves\u2019 disease. N Engl J Med. 2016;375(16):1552\u201365. https:\/\/doi.org\/10.1056\/NEJMra1510030.","journal-title":"N Engl J Med"},{"key":"1194_CR32","doi-asserted-by":"publisher","unstructured":"Douglas RS, McCoy AN, Gupta S, et al. Thyroid Eye Disease. Springer New York, NY; 2015. https:\/\/doi.org\/10.1007\/978-1-4939-1746-4\u00a0","DOI":"10.1007\/978-1-4939-1746-4"},{"key":"1194_CR33","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1016\/j.ajo.2019.07.021","volume":"208","author":"A Patel","year":"2019","unstructured":"Patel A, Yang H, Douglas RS. A new era in the treatment of thyroid eye disease. Am J Ophthalmol. 2019;208:281\u20138. https:\/\/doi.org\/10.1016\/j.ajo.2019.07.021.","journal-title":"Am J Ophthalmol"},{"issue":"4","key":"1194_CR34","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1056\/NEJMoa1910434","volume":"382","author":"RS Douglas","year":"2020","unstructured":"\u2022\u2022 Douglas RS, Kahaly GJ, Patel A, et al. Teprotumumab for the treatment of active thyroid eye disease. N Engl J Med. 2020;382(4):341\u201352. https:\/\/doi.org\/10.1056\/NEJMoa1910434. This stage 3 trial demonstrated teprotumumab\u2019s resounding efficacy for improving proptosis, diplopia, and CAS score in patients with moderate-to-severe TED.","journal-title":"N Engl J Med"},{"issue":"18","key":"1194_CR35","doi-asserted-by":"publisher","first-page":"1748","DOI":"10.1056\/NEJMoa1614949","volume":"376","author":"TJ Smith","year":"2017","unstructured":"Smith TJ, Kahaly GJ, Ezra DG, et al. Teprotumumab for thyroid-associated ophthalmopathy. N Engl J Med. 2017;376(18):1748\u201361. https:\/\/doi.org\/10.1056\/NEJMoa1614949.","journal-title":"N Engl J Med"},{"issue":"6","key":"1194_CR36","first-page":"269","volume":"19","author":"CM Skov","year":"1984","unstructured":"Skov CM, Mazow ML. Managing strabismus in endocrine eye disease. Can J Ophthalmol. 1984;19(6):269\u201374.","journal-title":"Can J Ophthalmol"},{"issue":"2","key":"1194_CR37","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1016\/S0889-8529(18)30485-7","volume":"16","author":"RS Bahn","year":"1987","unstructured":"Bahn RS, Gorman CA. Choice of therapy and criteria for assessing treatment outcome in thyroid-associated ophthalmopathy. Endocrinol Metab Clin North Am. 1987;16(2):391\u2013407.","journal-title":"Endocrinol Metab Clin North Am"},{"issue":"2","key":"1194_CR38","doi-asserted-by":"publisher","first-page":"79","DOI":"10.4103\/kjo.kjo_84_17","volume":"29","author":"J Antony","year":"2017","unstructured":"Antony J. Prisms in clinical practice. Kerala J Ophthalmol. 2017;29(2):79.","journal-title":"Kerala J Ophthalmol"},{"issue":"11","key":"1194_CR39","doi-asserted-by":"publisher","first-page":"1515","DOI":"10.1016\/s0161-6420(88)32978-7","volume":"95","author":"JM Neigel","year":"1988","unstructured":"Neigel JM, Rootman J, Belkin RI, et al. Dysthyroid optic neuropathy The crowded orbital apex syndrome. Ophthalmology. 1988;95(11):1515\u201321. https:\/\/doi.org\/10.1016\/s0161-6420(88)32978-7.","journal-title":"Ophthalmology"},{"issue":"2","key":"1194_CR40","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1080\/17469899.2017.1276444","volume":"12","author":"AD Blandford","year":"2017","unstructured":"Blandford AD, Zhang D, Chundury RV, Perry JD. Dysthyroid optic neuropathy: update on pathogenesis, diagnosis, and management. Expert Rev Ophthalmol. 2017;12(2):111\u201321. https:\/\/doi.org\/10.1080\/17469899.2017.1276444.","journal-title":"Expert Rev Ophthalmol"},{"issue":"2","key":"1194_CR41","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1097\/IOP.0000000000001501","volume":"36","author":"GE Rose","year":"2020","unstructured":"Rose GE, Vahdani K. Optic nerve stretch is unlikely to be a significant causative factor in dysthyroid optic neuropathy. Ophthalmic Plast Reconstr Surg. 2020;36(2):157\u201363. https:\/\/doi.org\/10.1097\/IOP.0000000000001501.","journal-title":"Ophthalmic Plast Reconstr Surg"},{"issue":"2","key":"1194_CR42","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1177\/112067211002000226","volume":"20","author":"CR Soni","year":"2010","unstructured":"Soni CR, Johnson LN. Visual neuropraxia and progressive vision loss from thyroid-associated stretch optic neuropathy. Eur J Ophthalmol. 2010;20(2):429\u201336. https:\/\/doi.org\/10.1177\/112067211002000226.","journal-title":"Eur J Ophthalmol"},{"issue":"8","key":"1194_CR43","doi-asserted-by":"publisher","first-page":"568","DOI":"10.3928\/1542-8877-19890801-09","volume":"20","author":"RL Anderson","year":"1989","unstructured":"Anderson RL, Tweeten JP, Patrinely JR, Garland PE, Thiese SM. Dysthyroid optic neuropathy without extraocular muscle involvement. Ophthalmic Surg Lasers Imaging Retina. 1989;20(8):568\u201374. https:\/\/doi.org\/10.3928\/1542-8877-19890801-09.","journal-title":"Ophthalmic Surg Lasers Imaging Retina"},{"issue":"4","key":"1194_CR44","doi-asserted-by":"publisher","first-page":"G43","DOI":"10.1530\/EJE-21-0479","volume":"185","author":"L Bartalena","year":"2021","unstructured":"\u2022\u2022 Bartalena L, Kahaly GJ, Baldeschi L, et al. The 2021 European Group on Graves\u2019 orbitopathy (EUGOGO) clinical practice guidelines for the medical management of Graves\u2019 orbitopathy. Eur J Endocrinol. 2021;185(4):G43\u201367. https:\/\/doi.org\/10.1530\/EJE-21-0479. This paper updates the most cited guidelines on assessment and management of TED for 2021.","journal-title":"Eur J Endocrinol"},{"issue":"1","key":"1194_CR45","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1159\/000443828","volume":"5","author":"L Bartalena","year":"2016","unstructured":"Bartalena L, Baldeschi L, Boboridis K, et al. The 2016 European Thyroid Association\/European Group on Graves\u2019 Orbitopathy guidelines for the management of Graves\u2019 orbitopathy. Eur Thyroid J. 2016;5(1):9\u201326. https:\/\/doi.org\/10.1159\/000443828.","journal-title":"Eur Thyroid J"},{"issue":"9","key":"1194_CR46","doi-asserted-by":"publisher","first-page":"5234","DOI":"10.1210\/jc.2005-0148","volume":"90","author":"GJ Kahaly","year":"2005","unstructured":"Kahaly GJ, Pitz S, Hommel G, Dittmar M. Randomized, single blind trial of intravenous versus oral steroid monotherapy in Graves\u2019 orbitopathy. J Clin Endocrinol Metab. 2005;90(9):5234\u201340. https:\/\/doi.org\/10.1210\/jc.2005-0148.","journal-title":"J Clin Endocrinol Metab"},{"key":"1194_CR47","doi-asserted-by":"publisher","first-page":"251584142110277","DOI":"10.1177\/25158414211027760","volume":"13","author":"CJ Men","year":"2021","unstructured":"\u2022 Men CJ, Kossler AL, Wester ST. Updates on the understanding and management of thyroid eye disease. Ther Adv Ophthalmol. 2021;13:25158414211027760. https:\/\/doi.org\/10.1177\/25158414211027760. This review details new and upcoming therapies for thyroid eye disease.","journal-title":"Ther Adv Ophthalmol"},{"issue":"2","key":"1194_CR48","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1210\/jc.2010-1962","volume":"96","author":"S Zang","year":"2011","unstructured":"Zang S, Ponto KA, Kahaly GJ. Clinical review: intravenous glucocorticoids for Graves\u2019 orbitopathy: efficacy and morbidity. J Clin Endocrinol Metab. 2011;96(2):320\u201332. https:\/\/doi.org\/10.1210\/jc.2010-1962.","journal-title":"J Clin Endocrinol Metab"},{"issue":"8","key":"1194_CR49","doi-asserted-by":"publisher","first-page":"3562","DOI":"10.1210\/jcem.86.8.7737","volume":"86","author":"C Marcocci","year":"2001","unstructured":"Marcocci C, Bartalena L, Tanda ML, et al. Comparison of the effectiveness and tolerability of intravenous or oral glucocorticoids associated with orbital radiotherapy in the management of severe Graves\u2019 ophthalmopathy: results of a prospective, single-blind, randomized study. J Clin Endocrinol Metab. 2001;86(8):3562\u20137. https:\/\/doi.org\/10.1210\/jcem.86.8.7737.","journal-title":"J Clin Endocrinol Metab"},{"issue":"2\u20133","key":"1194_CR50","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/s0162-3109(00)00188-0","volume":"47","author":"AC Allison","year":"2000","unstructured":"Allison AC, Eugui EM. Mycophenolate mofetil and its mechanisms of action. Immunopharmacology. 2000;47(2\u20133):85\u2013118. https:\/\/doi.org\/10.1016\/s0162-3109(00)00188-0.","journal-title":"Immunopharmacology"},{"issue":"4","key":"1194_CR51","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1016\/s2213-8587(18)30020-2","volume":"6","author":"GJ Kahaly","year":"2018","unstructured":"\u2022 Kahaly GJ, Riedl M, K\u00f6nig J, et al. Mycophenolate plus methylprednisolone versus methylprednisolone alone in active, moderate-to-severe Graves\u2019 orbitopathy (MINGO): a randomised, observer-masked, multicentre trial. Lancet Diabetes Endocrinol. 2018;6(4):287\u201398. https:\/\/doi.org\/10.1016\/s2213-8587(18)30020-2. The authors conducted a large RCT demonstrating efficacy of MMF added onto IVMP in terms of composite ophthalmic score but not in terms of diplopia specifically.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"2","key":"1194_CR52","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1111\/cen.13170","volume":"86","author":"X Ye","year":"2017","unstructured":"\u2022 Ye X, Bo X, Hu X, et al. Efficacy and safety of mycophenolate mofetil in patients with active moderate-to-severe Graves\u2019 orbitopathy. Clin Endocrinol (Oxf). 2017;86(2):247\u201355. https:\/\/doi.org\/10.1111\/cen.13170. The results of a large RCT demonstrated significantly improved inflammation and diplopia in patients treated with MMF monotherapy compared to IVMP + oral steroid taper.","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"6","key":"1194_CR53","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1007\/s40618-019-01161-z","volume":"43","author":"ACH Lee","year":"2020","unstructured":"Lee ACH, Riedl M, Frommer L, Diana T, Kahaly GJ. Systemic safety analysis of mycophenolate in Graves\u2019 orbitopathy. J Endocrinol Invest. 2020;43(6):767\u201377. https:\/\/doi.org\/10.1007\/s40618-019-01161-z.","journal-title":"J Endocrinol Invest"},{"key":"1194_CR54","doi-asserted-by":"publisher","first-page":"1921","DOI":"10.2147\/opth.S305717","volume":"15","author":"N Quah Qin Xian","year":"2021","unstructured":"Quah Qin Xian N, Alnahrawy A, Akshikar R, Lee V. Real-world efficacy and safety of mycophenolate mofetil in active moderate-to-sight-threatening thyroid eye disease. Clin Ophthalmol. 2021;15:1921\u201332. https:\/\/doi.org\/10.2147\/opth.S305717.","journal-title":"Clin Ophthalmol"},{"issue":"6","key":"1194_CR55","doi-asserted-by":"publisher","first-page":"1299","DOI":"10.1016\/j.ajo.2014.02.044","volume":"157","author":"PN Shams","year":"2014","unstructured":"Shams PN, Ma R, Pickles T, Rootman J, Dolman PJ. Reduced risk of compressive optic neuropathy using orbital radiotherapy in patients with active thyroid eye disease. Am J Ophthalmol. 2014;157(6):1299\u2013305. https:\/\/doi.org\/10.1016\/j.ajo.2014.02.044.","journal-title":"Am J Ophthalmol"},{"issue":"6","key":"1194_CR56","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.1210\/jcem-56-6-1139","volume":"56","author":"L Bartalena","year":"1983","unstructured":"Bartalena L, Marcocci C, Chiovato L, et al. Orbital cobalt irradiation combined with systemic corticosteroids for Graves\u2019 ophthalmopathy: comparison with systemic corticosteroids alone*. J Clin Endocrinol Metab. 1983;56(6):1139\u201344. https:\/\/doi.org\/10.1210\/jcem-56-6-1139.","journal-title":"J Clin Endocrinol Metab"},{"key":"1194_CR57","doi-asserted-by":"publisher","first-page":"4845894","DOI":"10.1155\/2018\/4845894","volume":"2018","author":"X Tu","year":"2018","unstructured":"Tu X, Dong Y, Zhang H, Su Q. Corticosteroids for Graves\u2019 ophthalmopathy: systematic review and meta-analysis. BioMed Re Int. 2018;2018:4845894. https:\/\/doi.org\/10.1155\/2018\/4845894.","journal-title":"BioMed Re Int"},{"issue":"5","key":"1194_CR58","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1097\/med.0000000000000493","volume":"26","author":"GJ Kahaly","year":"2019","unstructured":"Kahaly GJ. Immunotherapies for thyroid eye disease. Curr Opin Endocrinol Diabetes Obes. 2019;26(5):250\u20135. https:\/\/doi.org\/10.1097\/med.0000000000000493.","journal-title":"Curr Opin Endocrinol Diabetes Obes"},{"issue":"2","key":"1194_CR59","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1210\/jc.2014-2572","volume":"100","author":"MN Stan","year":"2015","unstructured":"Stan MN, Garrity JA, Carranza Leon BG, Prabin T, Bradley EA, Bahn RS. Randomized controlled trial of rituximab in patients with Graves\u2019 orbitopathy. J Clin Endocrinol Metab. 2015;100(2):432\u201341. https:\/\/doi.org\/10.1210\/jc.2014-2572.","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"1194_CR60","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1210\/jc.2014-3014","volume":"100","author":"M Salvi","year":"2015","unstructured":"Salvi M, Vannucchi G, Curro N, et al. Efficacy of B-cell targeted therapy with rituximab in patients with active moderate to severe Graves\u2019 orbitopathy: a randomized controlled study. J Clin Endocrinol Metab. 2015;100(2):422\u201331. https:\/\/doi.org\/10.1210\/jc.2014-3014.","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"1194_CR61","doi-asserted-by":"publisher","first-page":"R101","DOI":"10.1530\/EJE-16-0552","volume":"176","author":"MN Stan","year":"2017","unstructured":"Stan MN, Salvi M. Management of endocrine disease: rituximab therapy for Graves\u2019 orbitopathy - lessons from randomized control trials. Eur J Endocrinol. 2017;176(2):R101\u20139. https:\/\/doi.org\/10.1530\/EJE-16-0552.","journal-title":"Eur J Endocrinol"},{"issue":"5","key":"1194_CR62","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1089\/thy.2020.0269","volume":"31","author":"G Vannucchi","year":"2021","unstructured":"Vannucchi G, Campi I, Covelli D, et al. Efficacy profile and safety of very low-dose rituximab in patients with Graves\u2019 orbitopathy. Thyroid. 2021;31(5):821\u20138. https:\/\/doi.org\/10.1089\/thy.2020.0269.","journal-title":"Thyroid"},{"issue":"9","key":"1194_CR63","doi-asserted-by":"publisher","first-page":"2013","DOI":"10.1007\/s00417-020-04651-6","volume":"258","author":"JB Deltour","year":"2020","unstructured":"Deltour JB, d\u2019Assigny Flamen M, Ladsous M, et al. Efficacy of rituximab in patients with Graves\u2019 orbitopathy: a retrospective multicenter nationwide study. Graefes Arch Clin Exp Ophthalmol. 2020;258(9):2013\u201321. https:\/\/doi.org\/10.1007\/s00417-020-04651-6.","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"1194_CR64","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/j.ajo.2018.07.038","volume":"195","author":"JV Perez-Moreiras","year":"2018","unstructured":"\u2022 Perez-Moreiras JV, Gomez-Reino JJ, Maneiro JR, et al. Efficacy of tocilizumab in patients with moderate-to-severe corticosteroid-resistant Graves orbitopathy: a randomized clinical trial. Am J Ophthalmol. 2018;195:181\u201390. https:\/\/doi.org\/10.1016\/j.ajo.2018.07.038. This is the only tocilizumab RCT which demonstrated tocilizumab\u2019s efficacy for improving orbital inflammation but not for diplopia.","journal-title":"Am J Ophthalmol"},{"issue":"12","key":"1194_CR65","doi-asserted-by":"publisher","first-page":"4454","DOI":"10.1210\/jc.2012-2389","volume":"97","author":"L Bartalena","year":"2012","unstructured":"Bartalena L, Krassas G, Wiersinga W, et al. Efficacy and safety of three different cumulative doses of intravenous methylprednisolone for moderate to severe and active Graves\u2019 orbitopathy. J Clin Endocrinol Metab. 2012;97(12):4454\u201363.","journal-title":"J Clin Endocrinol Metab"},{"issue":"11","key":"1194_CR66","doi-asserted-by":"publisher","first-page":"1380","DOI":"10.1136\/bjo.2004.046193","volume":"88","author":"R Ebner","year":"2004","unstructured":"Ebner R, Devoto MH, Weil D, et al. Treatment of thyroid associated ophthalmopathy with periocular injections of triamcinolone. Br J Ophthalmol. 2004;88(11):1380\u20136. https:\/\/doi.org\/10.1136\/bjo.2004.046193.","journal-title":"Br J Ophthalmol"},{"issue":"9214","key":"1194_CR67","doi-asserted-by":"publisher","first-page":"1505","DOI":"10.1016\/s0140-6736(00)02165-6","volume":"355","author":"MP Mourits","year":"2000","unstructured":"Mourits MP, van Kempen-Harteveld ML, Garc\u00eda MB, Koppeschaar HP, Tick L, Terwee CB. Radiotherapy for Graves\u2019 orbitopathy: randomised placebo-controlled study. Lancet. 2000;355(9214):1505\u20139. https:\/\/doi.org\/10.1016\/s0140-6736(00)02165-6.","journal-title":"Lancet"},{"issue":"1","key":"1194_CR68","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1210\/jc.2003-030809","volume":"89","author":"MF Prummel","year":"2004","unstructured":"Prummel MF, Terwee CB, Gerding MN, et al. A randomized controlled trial of orbital radiotherapy versus sham irradiation in patients with mild Graves\u2019 ophthalmopathy. J Clin Endocrinol Metab. 2004;89(1):15\u201320. https:\/\/doi.org\/10.1210\/jc.2003-030809.","journal-title":"J Clin Endocrinol Metab"},{"issue":"4s","key":"1194_CR69","doi-asserted-by":"publisher","first-page":"S160","DOI":"10.1016\/j.ophtha.2020.01.031","volume":"127","author":"CA Gorman","year":"2020","unstructured":"Gorman CA, Garrity JA, Fatourechi V, et al. A prospective, randomized, double-blind, placebo-controlled study of orbital radiotherapy for Graves\u2019 ophthalmopathy. Ophthalmology. 2020;127(4s):S160-s171. https:\/\/doi.org\/10.1016\/j.ophtha.2020.01.031.","journal-title":"Ophthalmology"},{"issue":"4","key":"1194_CR70","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1016\/s2213-8587(18)30021-4","volume":"6","author":"R Rajendram","year":"2018","unstructured":"Rajendram R, Taylor PN, Wilson VJ, et al. Combined immunosuppression and radiotherapy in thyroid eye disease (CIRTED): a multicentre, 2 \u00d7 2 factorial, double-blind, randomised controlled trial. Lancet Diabetes Endocrinol. 2018;6(4):299\u2013309. https:\/\/doi.org\/10.1016\/s2213-8587(18)30021-4.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"Suppl 1","key":"1194_CR71","first-page":"A1","volume":"28","author":"G Kahaly","year":"2018","unstructured":"\u2022\u2022 Kahaly G, Douglas R, Holt R, Perdok R, Ball J, Smith T. 48-Week follow-up of a multicenter, randomized, double-masked, placebo-controlled treatment trial of teprotumumab in thyroid-associated ophthalmopathy. Thyroid. 2018;28(Suppl 1):A1. This review pools and analyzes the results of the two landmark teprotumumab clinical trials.","journal-title":"Thyroid"},{"key":"1194_CR72","unstructured":"Douglas RS, Holt RJ, Vescio T, et al. Long-term assessment of proptosis and diplopia from the OPTIC trial of teprotumumab in thyroid eye disease. In: American Academy of Ophthalmology, AAO. Presented at: AAO 2020 Virtual; 2020."},{"key":"1194_CR73","unstructured":"Sears CM, Amarikwa L, Men CJ,\u00a0 et al. Teprotumumab for the treatment of recalcitrant thyroid eye disease. Presented at: ASOPRS 52nd Annual Fall Scientific Symposium. New Orleans;\u00a02021."},{"issue":"5","key":"1194_CR74","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1097\/icu.0000000000000513","volume":"29","author":"MJ Bartiss","year":"2018","unstructured":"Bartiss MJ. Nonsurgical treatment of diplopia. Curr Opin Ophthalmol. 2018;29(5):381\u20134. https:\/\/doi.org\/10.1097\/icu.0000000000000513.","journal-title":"Curr Opin Ophthalmol"},{"issue":"5","key":"1194_CR75","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1007\/s00417-016-3281-6","volume":"254","author":"DB Granet","year":"2016","unstructured":"Granet DB, Hodgson N, Godfrey KJ, et al. Chemodenervation of extraocular muscles with botulinum toxin in thyroid eye disease. Graefes Arch Clin Exp Ophthalmol. 2016;254(5):999\u20131003. https:\/\/doi.org\/10.1007\/s00417-016-3281-6.","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"issue":"2","key":"1194_CR76","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1016\/j.jaapos.2016.01.007","volume":"20","author":"MR Akbari","year":"2016","unstructured":"Akbari MR, Ameri A, Keshtkar Jaafari AR, Mirmohammadsadeghi A. Botulinum toxin injection for restrictive myopathy of thyroid-associated orbitopathy: success rate and predictive factors. J AAPOS. 2016;20(2):126-130.e1. https:\/\/doi.org\/10.1016\/j.jaapos.2016.01.007.","journal-title":"J AAPOS"},{"issue":"2","key":"1194_CR77","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1097\/iio.0000000000000350","volume":"61","author":"RN Maamari","year":"2021","unstructured":"Maamari RN, Couch SM. Combined orbital decompression and strabismus surgery in thyroid eye disease. Int Ophthalmol Clin. 2021;61(2):127\u201336. https:\/\/doi.org\/10.1097\/iio.0000000000000350.","journal-title":"Int Ophthalmol Clin"},{"issue":"4","key":"1194_CR78","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1097\/00002341-200007000-00004","volume":"16","author":"RA Goldberg","year":"2000","unstructured":"Goldberg RA, Perry JD, Hortaleza V, Tong JT. Strabismus after balanced medial plus lateral wall versus lateral wall only orbital decompression for dysthyroid orbitopathy. Ophthalmic Plast Reconstr Surg. 2000;16(4):271\u20137. https:\/\/doi.org\/10.1097\/00002341-200007000-00004.","journal-title":"Ophthalmic Plast Reconstr Surg"},{"issue":"2","key":"1194_CR79","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1038\/eye.2014.282","volume":"29","author":"R Harrad","year":"2015","unstructured":"Harrad R. Management of strabismus in thyroid eye disease. Eye (Lond). 2015;29(2):234\u20137. https:\/\/doi.org\/10.1038\/eye.2014.282.","journal-title":"Eye (Lond)"},{"key":"1194_CR80","doi-asserted-by":"publisher","DOI":"10.1097\/IOP.0000000000001959","author":"SB Diniz","year":"2021","unstructured":"\u2022 Diniz SB, Cohen LM, Roelofs KA, Rootman DB. Early experience with the clinical use of teprotumumab in a heterogenous thyroid eye disease population. Ophthalmic Plast Reconstr Surg. 2021. https:\/\/doi.org\/10.1097\/IOP.0000000000001959. This is the first paper demonstrating teprotumumab\u2019s efficacy on a heterogeneous patient population regardless of stage or grade of disease.","journal-title":"Ophthalmic Plast Reconstr Surg"},{"key":"1194_CR81","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajoc.2020.100744","volume":"19","author":"DJ Ozzello","year":"2020","unstructured":"\u2022 Ozzello DJ, Kikkawa DO, Korn BS. Early experience with teprotumumab for chronic thyroid eye disease. Am J Ophthalmol Case Rep. 2020;19: 100744. https:\/\/doi.org\/10.1016\/j.ajoc.2020.100744. This case report details the first case in the literature of a patient with chronic TED treated with teprotumumab.","journal-title":"Am J Ophthalmol Case Rep"},{"key":"1194_CR82","doi-asserted-by":"publisher","DOI":"10.1038\/s41433-021-01593-z","author":"S Ugradar","year":"2021","unstructured":"\u2022\u2022 Ugradar S, Kang J, Kossler AL, et al. Teprotumumab for the treatment of chronic thyroid eye disease. Eye. 2021. https:\/\/doi.org\/10.1038\/s41433-021-01593-z. The authors conducted the largest study to date of teprotumumab, demonstrating its efficacy for chronic TED in terms of overall inflammation as well as diplopia.","journal-title":"Eye"},{"issue":"11","key":"1194_CR83","doi-asserted-by":"publisher","first-page":"4079","DOI":"10.1210\/jcem.84.11.6111","volume":"84","author":"LA Kaback","year":"1999","unstructured":"Kaback LA, Smith TJ. Expression of hyaluronan synthase messenger ribonucleic acids and their induction by interleukin-1beta in human orbital fibroblasts: potential insight into the molecular pathogenesis of thyroid-associated ophthalmopathy. J Clin Endocrinol Metab. 1999;84(11):4079\u201384. https:\/\/doi.org\/10.1210\/jcem.84.11.6111.","journal-title":"J Clin Endocrinol Metab"},{"key":"1194_CR84","doi-asserted-by":"publisher","unstructured":"Wakelkamp IM, Baldeschi L, Saeed P, Mourits MP, Prummel MF, Wiersinga WM. Surgical or medical decompression as a first-line treatment of optic neuropathy in Graves' ophthalmopathy? A randomized controlled trial. Clin Endocrinol (Oxf). Sep 2005;63(3):323\u20138. https:\/\/doi.org\/10.1111\/j.1365-2265.2005.02345.","DOI":"10.1111\/j.1365-2265.2005.02345"},{"issue":"4","key":"1194_CR85","doi-asserted-by":"publisher","first-page":"253","DOI":"10.3109\/01676838909012334","volume":"8","author":"A Threlkeld","year":"2009","unstructured":"Threlkeld A, Miller NR, Wharam M. The efficacy of supervoltage radiation therapy in the treatment of dysthyroid optic neuropathy. Orbit. 2009;8(4):253\u201364. https:\/\/doi.org\/10.3109\/01676838909012334.","journal-title":"Orbit"},{"issue":"4","key":"1194_CR86","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1016\/s0360-3016(98)00405-2","volume":"43","author":"V Beckendorf","year":"1999","unstructured":"Beckendorf V, Maalouf T, George J-L, Bey P, Leclere J, Luporsi E. Place of radiotherapy in the treatment of Graves\u2019 orbitopathy. Int J Radiat Oncol Biol Phys. 1999;43(4):805\u201315. https:\/\/doi.org\/10.1016\/s0360-3016(98)00405-2.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"2","key":"1194_CR87","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1097\/WNO.0b013e318255d7c7","volume":"32","author":"M Kazim","year":"2012","unstructured":"Kazim M, Garrity JA. Orbital radiation therapy for thyroid eye disease. J Neuroophthalmol. 2012;32(2):172\u20136. https:\/\/doi.org\/10.1097\/WNO.0b013e318255d7c7.","journal-title":"J Neuroophthalmol"},{"issue":"1","key":"1194_CR88","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/s0360-3016(99)00528-3","volume":"47","author":"S Rush","year":"2000","unstructured":"Rush S, Winterkorn JMS, Zak R. Objective evaluation of improvement in optic neuropathy following radiation therapy for thyroid eye disease. Int J Radiat Oncol Biol Phys. 2000;47(1):191\u20134. https:\/\/doi.org\/10.1016\/s0360-3016(99)00528-3.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"1","key":"1194_CR89","doi-asserted-by":"publisher","first-page":"17533","DOI":"10.1038\/s41598-017-17893-y","volume":"7","author":"YJ Li","year":"2017","unstructured":"Li YJ, Luo Y, Xie XQ, et al. The efficacy of intensity modulated radiation therapy in treating thyroid-associated ophthalmopathy and predictive factors for treatment response. Sci Rep. 2017;7(1):17533. https:\/\/doi.org\/10.1038\/s41598-017-17893-y.","journal-title":"Sci Rep"},{"issue":"1","key":"1194_CR90","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/j.ijrobp.2010.08.053","volume":"82","author":"C Matthiesen","year":"2012","unstructured":"Matthiesen C, Thompson JS, Thompson D, et al. The efficacy of radiation therapy in the treatment of Graves\u2019 orbitopathy. Int J Radiat Oncol Biol Phys. 2012;82(1):117\u201323. https:\/\/doi.org\/10.1016\/j.ijrobp.2010.08.053.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"1","key":"1194_CR91","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1186\/s13014-020-01663-8","volume":"15","author":"JH Choi","year":"2020","unstructured":"Choi JH, Lee JK. Efficacy of orbital radiotherapy in moderate-to-severe active Graves\u2019 orbitopathy including long-lasting disease: a retrospective analysis. Radiat Oncol. 2020;15(1):220. https:\/\/doi.org\/10.1186\/s13014-020-01663-8.","journal-title":"Radiat Oncol"},{"issue":"2","key":"1194_CR92","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1097\/IOP.0000000000001003","volume":"34","author":"KG Gold","year":"2018","unstructured":"\u2022 Gold KG, Scofield S, Isaacson SR, Stewart MW, Kazim M. Orbital radiotherapy combined with corticosteroid treatment for thyroid eye disease-compressive optic neuropathy. Ophthalmic Plast Reconstr Surg. 2018;34(2):172\u20137. https:\/\/doi.org\/10.1097\/IOP.0000000000001003. The authors conducted the largest retrospective study to date detailing the response to treatment in DON patients treated with combined steroids and ORT, which other reports have suggested have a synergistic effect.","journal-title":"Ophthalmic Plast Reconstr Surg"},{"issue":"4S Suppl 1","key":"1194_CR93","doi-asserted-by":"publisher","first-page":"S98","DOI":"10.1097\/IOP.0000000000001074","volume":"34","author":"KJ Godfrey","year":"2018","unstructured":"Godfrey KJ, Kazim M. Radiotherapy for active thyroid eye disease. Ophthalmic Plast Reconstr Surg. 2018;34(4S Suppl 1):S98\u2013104. https:\/\/doi.org\/10.1097\/IOP.0000000000001074.","journal-title":"Ophthalmic Plast Reconstr Surg"},{"issue":"10","key":"1194_CR94","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1007\/BF03347943","volume":"14","author":"C Marcocci","year":"1991","unstructured":"Marcocci C, Bartalena L, Bogazzi F, Bruno-Bossio G, Lepri A, Pinchera A. Orbital radiotherapy combined with high dose systemic glucocorticoids for Graves\u2019 ophthalmopathy is more effective than radiotherapy alone: results of a prospective randomized study. J Endocrinol Invest. 1991;14(10):853\u201360. https:\/\/doi.org\/10.1007\/BF03347943.","journal-title":"J Endocrinol Invest"},{"issue":"1","key":"1194_CR95","doi-asserted-by":"publisher","DOI":"10.5812\/ijem.84427","volume":"17","author":"L Nicosia","year":"2019","unstructured":"Nicosia L, Reverberi C, Agolli L, et al. Orbital radiotherapy plus concomitant steroids in moderate-to-severe Graves\u2019 ophthalmopathy: good results after long-term follow-up. Int J Endocrinol Metab. 2019;17(1): e84427. https:\/\/doi.org\/10.5812\/ijem.84427.","journal-title":"Int J Endocrinol Metab"},{"issue":"1","key":"1194_CR96","doi-asserted-by":"publisher","first-page":"2027","DOI":"10.1038\/s41598-019-38640-5","volume":"9","author":"M Ito","year":"2019","unstructured":"Ito M, Takahashi Y, Katsuda E, et al. Predictive factors of prognosis after radiation and steroid pulse therapy in thyroid eye disease. Sci Rep. 2019;9(1):2027. https:\/\/doi.org\/10.1038\/s41598-019-38640-5.","journal-title":"Sci Rep"},{"issue":"1","key":"1194_CR97","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1016\/j.survophthal.2017.03.007","volume":"63","author":"DB Rootman","year":"2018","unstructured":"Rootman DB. Orbital decompression for thyroid eye disease. Surv Ophthalmol. 2018;63(1):86\u2013104. https:\/\/doi.org\/10.1016\/j.survophthal.2017.03.007.","journal-title":"Surv Ophthalmol"},{"issue":"7","key":"1194_CR98","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1007\/s12325-015-0228-y","volume":"32","author":"KG Boboridis","year":"2015","unstructured":"Boboridis KG, Uddin J, Mikropoulos DG, et al. Critical appraisal on orbital decompression for thyroid eye disease: a systematic review and literature search. Adv Ther. 2015;32(7):595\u2013611. https:\/\/doi.org\/10.1007\/s12325-015-0228-y.","journal-title":"Adv Ther"},{"issue":"9","key":"1194_CR99","doi-asserted-by":"publisher","first-page":"1702","DOI":"10.1038\/s41433-020-0897-x","volume":"34","author":"A Garip Kuebler","year":"2020","unstructured":"Garip Kuebler A, Wiecha C, Reznicek L, et al. Evaluation of medical and surgical decompression in patients with dysthyroid optic neuropathy. Eye (Lond). 2020;34(9):1702\u20139. https:\/\/doi.org\/10.1038\/s41433-020-0897-x.","journal-title":"Eye (Lond)"},{"key":"1194_CR100","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2020.583565","volume":"11","author":"B Zhang","year":"2020","unstructured":"Zhang B, Li Y, Xu W, Peng B, Yuan G. Use of rituximab after orbital decompression surgery in two Grave\u2019s ophthalmopathy patients progressing to optic neuropathy. Front Endocrinol (Lausanne). 2020;11: 583565. https:\/\/doi.org\/10.3389\/fendo.2020.583565.","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"1","key":"1194_CR101","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1111\/cen.13970","volume":"91","author":"EA Insull","year":"2019","unstructured":"Insull EA, Sipkova Z, David J, Turner HE, Norris JH. Early low-dose rituximab for active thyroid eye disease: an effective and well-tolerated treatment. Clin Endocrinol (Oxf). 2019;91(1):179\u201386. https:\/\/doi.org\/10.1111\/cen.13970.","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"1","key":"1194_CR102","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.ando.2016.12.002","volume":"78","author":"F Pr\u00e9causta","year":"2017","unstructured":"Pr\u00e9causta F, Ars\u00e8ne S, Renoult-Pierre P, Laure B, Crini\u00e8re L, Pisella PJ. Treatment by rituximab on six Grave\u2019s ophthalmopathies resistant to corticosteroids. Ann Endocrinol (Paris). 2017;78(1):20\u20136. https:\/\/doi.org\/10.1016\/j.ando.2016.12.002.","journal-title":"Ann Endocrinol (Paris)"},{"issue":"6","key":"1194_CR103","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1080\/01676830.2018.1435694","volume":"37","author":"I Pascual-Camps","year":"2018","unstructured":"Pascual-Camps I, Molina-Pallete R, Bort-Mart\u00ed MA, Todol\u00ed J, Espa\u00f1a-Gregori E. Tocilizumab as first treatment option in optic neuropathy secondary to Graves\u2019 orbitopathy. Orbit. 2018;37(6):450\u20133. https:\/\/doi.org\/10.1080\/01676830.2018.1435694.","journal-title":"Orbit"},{"key":"1194_CR104","doi-asserted-by":"publisher","unstructured":"\u2022 Kaplan D, Erickson B, Kossler A, Chen J, Dosiou C. SAT-500 response to tocilizumab retreatment in refractory thyroid eye disease. J Endocrine Soc. 2020; 4(Supplement_1). https:\/\/doi.org\/10.1210\/jendso\/bvaa046.1316. The authors present the only report in the literature of a case that was retreated with tocilizumab.","DOI":"10.1210\/jendso\/bvaa046.1316"},{"key":"1194_CR105","doi-asserted-by":"publisher","unstructured":"S\u00e1nchez-Bilbao L, Mart\u00ednez-L\u00f3pez D, Revenga M, et al. Anti-IL-6 receptor tocilizumab in refractory Graves\u2019 orbitopathy: national multicenter observational study of 48 patients. J Clin Med. 2020;9(9). https:\/\/doi.org\/10.3390\/jcm9092816.","DOI":"10.3390\/jcm9092816"},{"issue":"2","key":"1194_CR106","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1080\/09273948.2018.1545914","volume":"28","author":"T Maldiney","year":"2020","unstructured":"Maldiney T, Deschasse C, Bielefeld P. Tocilizumab for the management of corticosteroid-resistant mild to severe Graves\u2019 ophthalmopathy, a report of three cases. Ocul Immunol Inflamm. 2020;28(2):281\u20134. https:\/\/doi.org\/10.1080\/09273948.2018.1545914.","journal-title":"Ocul Immunol Inflamm"},{"key":"1194_CR107","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajoc.2021.101075","volume":"22","author":"CA Chiou","year":"2021","unstructured":"Chiou CA, Reshef ER, Freitag SK. Teprotumumab for the treatment of mild compressive optic neuropathy in thyroid eye disease: a report of two cases. Am J Ophthalmol Case Rep. 2021;22: 101075. https:\/\/doi.org\/10.1016\/j.ajoc.2021.101075.","journal-title":"Am J Ophthalmol Case Rep"},{"issue":"3s","key":"1194_CR108","doi-asserted-by":"publisher","first-page":"S157","DOI":"10.1097\/iop.0000000000001831","volume":"37","author":"CM Sears","year":"2021","unstructured":"Sears CM, Azad AD, Dosiou C, Kossler AL. Teprotumumab for dysthyroid optic neuropathy early response to therapy. Ophthalmic Plast Reconstr Surg. 2021;37(3s):S157-s160. https:\/\/doi.org\/10.1097\/iop.0000000000001831. This is the first published case of DON managed with teprotumumab, which demonstrated efficacy in a particularly severe case of DON.","journal-title":"Ophthalmic Plast Reconstr Surg"},{"key":"1194_CR109","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajoc.2021.101111","volume":"23","author":"CM Sears","year":"2021","unstructured":"\u2022\u2022 Sears CM, Wang Y, Bailey LA, et al. Early efficacy of teprotumumab for the treatment of dysthyroid optic neuropathy: a multicenter study. Am J Ophthalmol Case Rep. 2021;23: 101111. https:\/\/doi.org\/10.1016\/j.ajoc.2021.101111. The authors conducted the largest published study on DON patients treated with teprotumumab to date.","journal-title":"Am J Ophthalmol Case Rep"},{"key":"1194_CR110","doi-asserted-by":"publisher","DOI":"10.1097\/wno.0000000000001298","author":"MJ Lopez","year":"2021","unstructured":"Lopez MJ, Herring JL, Thomas C, Bertram BA, Thomas DA. Visual recovery of dysthyroid optic neuropathy with teprotumumab. J Neuroophthalmol. 2021. https:\/\/doi.org\/10.1097\/wno.0000000000001298.","journal-title":"J Neuroophthalmol"},{"key":"1194_CR111","doi-asserted-by":"publisher","unstructured":"Hwang CJ, Nichols EE, Chon BH, Perry JD. Bilateral dysthyroid compressive optic neuropathy responsive to teprotumumab. Eur J Ophthalmol. 2021:1120672121991042. https:\/\/doi.org\/10.1177\/1120672121991042.","DOI":"10.1177\/1120672121991042"},{"issue":"2","key":"1194_CR112","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1001\/jamaophthalmol.2020.5296","volume":"139","author":"DH Slentz","year":"2021","unstructured":"Slentz DH, Smith TJ, Kim DS, Joseph SS. Teprotumumab for optic neuropathy in thyroid eye disease. JAMA Ophthalmol. 2021;139(2):244\u20137. https:\/\/doi.org\/10.1001\/jamaophthalmol.2020.5296.","journal-title":"JAMA Ophthalmol"}],"container-title":["Current Neurology and Neuroscience Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11910-022-01194-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11910-022-01194-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11910-022-01194-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,7]],"date-time":"2022-06-07T21:06:21Z","timestamp":1654635981000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11910-022-01194-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,26]]},"references-count":112,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2022,6]]}},"alternative-id":["1194"],"URL":"https:\/\/doi.org\/10.1007\/s11910-022-01194-7","relation":{},"ISSN":["1528-4042","1534-6293"],"issn-type":[{"type":"print","value":"1528-4042"},{"type":"electronic","value":"1534-6293"}],"subject":[],"published":{"date-parts":[[2022,5,26]]},"assertion":[{"value":"28 March 2022","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 May 2022","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"Dr. Andrea Kossler is a consultant for Horizon Therapeutics and Immunovant Inc.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article does not contain any studies with human or animal subjects performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}}]}}